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1. Introduction 
With the use of molecular medicine as part of routine laboratory evaluation of patients, the 
diagnosis of infection with has undergone a metamorphosis in the last 30 years. However, it 
remains a debated process as molecular testing is to date not accepted as definitive in most 
clinical settings, and more historic testing methods like cell culture, has not been completely 
rendered redundant[1]. Infection with Chlamydia trachomatis is therefore a complex condition 
to diagnose, and requires a clear understanding of testing methods and the inherent 
advantages and disadvantages to each. The modern approach to the diagnosis of Chlamydia 
trachomatis typically involves a combination of assays as part of screening and 
confirmation[2]. 
Patients very often manifest very few clinical symptoms and rarely seek medical 
assistance. For this reason, continued transmission occurs to sexual partners[3] causing 
Chlamydia trachomatis  to be the most common sexually transmitted bacterial infection 
worldwide[3, 4]. Due to these disease and pathogen characteristics, prevalence of this 
pathogen seems to be increasing in both developing and developed countries[5-8]. Correct 
diagnosis of infection with Chlamydia trachomatis is essential as false negative results may 
have significant impact on societal health[9]. Chlamydial infections has been associated 
with a higher risk of acquiring HIV-1 infection[4, 10] as well as cervical cancer[11] and 
adverse outcomes with pregnancy[12, 13]. For these reasons, early correct diagnosis of 
infection with Chlamydia trachomatis is essential to prevent long-term sequelae 
associated with prolonged infection. 
2. Specimens, collection and transport 
2.1 Clinical specimens 
Chlamydia trachomatis is very often asymptomatic in female patients, but may present with 
cervicitis, endometritis, pelvic inflammatory disease or Bartholin abscesses[14, 15]. 
Urethritis and proctitis is often a secondary manifestation, found in conjunction with other 
sites of infection[16]. In heterosexual men, urethral infection accounts for most symptomatic 
cases[17, 18], with ascending infection causing epididymitis[19]. Among homo- and bisexual 
men, sites of infection are also predominantly the urethra[20], but further includes the 
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rectum[21].  Infection in infants may cause conjunctivitis as well as pneumonia, particularly 
in early infancy [22, 23].  Serovars L1-3 is associated with lymphogranulomavenereum 
(LGV), and is particularly prevalent in areas of Africa, Asia and South America[24]. 
Clinically, these patients present with a painless genital ulcer, which later progress to 
lymphadenopathy[24]. They occasionally develop systemic symptoms[25]. 
2.2 Specimen collection 
Chlamydiae are intracellular organisms, and it is therefore essential to obtain host cells with 
the clinical sample to so ensure yield of organisms[2]. The sensitivity and specificity of any 
test for Chlamydia trachomatis, is highly dependent on sampling and adequacy of the sample 
obtained[26-28]. This holds true irrespective of testing type, whether it be culture, where 
viable organisms need to be obtained, or nucleic acid based testing, where non-viable 
genetic material can be obtained[29]. Although relatively standardized methods for 
sampling is advocated for direct testing, certain commercially available tests have unique 
sampling requirements, stipulated in the package insert[2]. 
In women, the endocervix is most commonly targeted for obtaining samples for culture, 
by utilizing either a swab or a cytologic brush. In the case of swabs, careful consideration 
should be taken as certain types of swabs may actually inhibit growth by being directly 
toxic to either the organisms or the cell culture[30]. Similarly, wooden-shafted swabs also 
inhibit growth. Optimal sample can be obtained using Dacron, cotton, rayon or calcium 
alginate-tipped swabs with plastic shafts[31]. Prior to obtaining the sample, the cervical 
os should be cleared of secretions and discharges, to so reduce bacterial contamination 
and possible toxicity. This also improves the quality and ease of interpretation of direct 
fluorescent antibody stains[32, 33]. Sampling should be performed by inserting the swab 
approximately 1-2 cm into the cervical os, rotating it, and keeping it in situ for 15 to 30 
seconds. Using swabs are less likely to induce bleeding[34], which in itself may also 
inhibit culture, but typically has a lower cell yield than cytological brushes[28]. For this 
reason, some authors have advocated against the use of a cytological brush, provided 
sampling with a swab is performed adequately[35]. Furthermore, culture yields have 
been improved by combining endocervical with urethral sampling[36]. Sampling is 
similar to male urethral sampling, however, the swab is inserted only 1cm past the 
urethral opening[2]. 
In male patients, the anterior urethra is the site of choice for optimal sampling, especially for 
culture purposes.  A dry swab is inserted 3 to 4 cm past the meatal opening of the urethra, 
rotated and removed. It is important to note that urination should best be avoided for at 
least 1 hour prior to sampling, as this significantly reduces the yield of cells obtained during 
sampling[2].  
Cases of conjunctivitis should be investigated by first removing the gross purulent 
discharge. Thereafter, the eye should be swabbed on the palpebral conjunctival surface, to 
so obtains some epithelial cells[2].  
In cases of LGV, sampling can be in the form of swabs from ulcers, saline aspirates from the 
bubo or biopsies. To ensure adequacy of deep-seated ulcers, these biopsies may be best 
performed under direct vision through proctoscopy[37]. 
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2.3 Specimen transport 
Culture yield is significantly improved if samples are transported to the laboratory for 
processing within 48 hours, and kept at 2 to 8°C during this time. The practice of freezing 
samples should be restricted to settings where significant delay is expected, as freezing at -70°C 
is associated with up to 20% loss in viability, and freezing at -20°C even higher losses[30, 38]. 
Various formulations of transport media have been used[39-41] as it may improve yield. 
This is because it typically contains fetal bovine serum to improve viability as well as 
antimicrobials, to suppress growth by other organisms. The formulation used is similar to 
transport media used for rickettsiae, but not viral transport media, as this typically contains 
penicillin[39, 40, 42].  
2.4 Sampling for non-culture-based testing 
Although typically very similar to culture based testing, non-culture based testing requires 
sampling and transport as specified by the manufacturers for the particular assay[43, 44].  
Urine-based testing has also been advocated for molecular testing. This has the added 
advantage that simultaneous testing can be performed for other pathogens like Neisseria 
gonorrhea as well as being non-invasive. However, the yield on urine samples are greater if it 
is a first-catch sample obtained 1 to 2 hours after prior urination, to so increase the amount 
of columner epithelial cells[45, 46]. If sampling is performed in excess of 3 hours after last 
void, specificity and sensitivity is reduced in females, but in male patients, controversy still 
exists[47, 48]. Some authors have reported that preceding cleaning performed in culture 
samples for females, should not be performed in this setting to so improve yield[46]. Novel 
testing methods now include sampling the vaginal introitus or vulva with promising results. 
The major advantage to this is that patients can self-sample[49]. 
3. Laboratory methods  
3.1 Direct detection 
3.1.1 Culture-based testing 
Historically, culture-based testing was considered the gold standard for diagnosis of Chlamydia 
trachomatis, and specificity was considered to approach 100%[50-52]. This high specificity is at 
the cost of sensitivity, which in a best-case scenario is estimated at 70 to 85%[52]. Appropriate 
sampling and transport is absolutely essential to ensure organism viability.  
Culture is performed using cell monolayers in dram or shell vials. Cell types permissive to 
infection include McCoy cells[53-55], HeLa229 cells[56, 57] and BGMK cells[58, 59]. Certain 
pretreatment steps have been advocated to improve culture yield. These include 
administration of DEAE-dextran[56, 60], sonication[61] and centrifugation[60]. These cell 
cultures are maintained using Eagle’s minimal essential medium (EMEM) with additional 
amino acids, vitamins, glucose, foetal calf serum and L-glutamine[2]. Although blind 
passaging has been shown to improve recovery by 3 to 10%[62], it leads to a significantly 
delay in obtaining results.   
Following culture, the presence of Chlamydia trachomatis needs to be confirmed. Firstly, various 
stains have been used including various Romanovsky stains and iodine staining. These 
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methods lack sensitivity and specificity and require an experienced microscopist[54, 63, 64]. 
The iodine stain is based on the premise of glycogen binding. However, normal cervical cells 
also contain glycogen, and therefore may impact on specificity[2]. Fluorescent dye based 
confirmation shows improved sensitivity and specificity, as it utilizes fluorescently labeled 
antibodies targeting either the major outer membrane protein (MOMP) or the chlamydial 
lipopolysaccharide (LPS) following approximately 48 to 72 hours of incubation. Sensitivity 
seems to be higher with MOMP based assays, as these are more widely distributed on the cells 
within culture[1]. Alternatively, these methods can also be applied to shell vial based cultures, 
to so improve turn-around times of results and sensitivity[54, 55]. 
3.1.2 Antigen detection methods 
Wide arrays of validated immunoassays are currently available[65-77]. Direct fluorescent 
antibody (DFA) testing can be utilized directly on clinical samples. As for culture-based 
confirmation, two antigenic sites can be utilized as targets, namely the MOMP and LPS. 
Assays targeting the LPS are specific to Chlamydia spp and are not considered specific to 
Chlamydia trachomatis. These antigens are not as widely distributed as MOMP, and sensitivity 
of these assays are therefore inferior to those targeting MOMP[2]. The MOMP based assays 
show specificity for Chlamydia trachomatis. These assays are validated for use on endocervical 
smears and male urethral swabs[78-80] but can be applied to urethral samples[78, 81], 
conjunctival swabs[82, 83], rectal smears[84] and respiratory samples from infants[85, 86]. DFA 
testing is a rapid method, with the added advantage providing simultaneous information on 
the quality of the sample, by way of visualizing presence of columner epithelium in adequate 
samples. However, the process is laborious and requires an experienced microscopist[2]. 
Evaluation of DFA methods with external quality programs by the College of American 
Pathologist (ACP) showed significant variability in results depending on the experience level 
of the laboratory[80]. It has been clearly established that in the absence of a quality assurance 
program, more than 10% of samples will be of inadequate quality for processing[27, 35]. For 
this reason, specimen adequacy can be evaluated by direct examination of the sample – an 
advantage that only the DFA assays hold. 
Immunochemical detection (EIA) can be performed either directly, targeting LPS or 
indirectly, by detecting anti-Chlamydial antibodies (discussed later). The LPS antigen is 
more abundant albeit irregularly distributed as compared to MOMP antigen. Prior to 
performing the EIA assays, samples are lysed, releasing large amounts of LPS thereby 
improving sensitivity. However, cross-reaction may occur with gram negative organisms to 
the detriment of specificity[62, 87-89]. To alleviate this issue, some manufacturers produce 
blocking assays to verify all positive results[90]. With these assays, positive tests are 
repeated following a pretreatment step where Chlamydial-specific monoclonal antibodies 
are added to the sample. True positive results will test negative on blocking assays, where 
false positive results will remain positive[91]. 
Point-of-Care testing assays are also available. These assays utilize EIA technology targeting 
LPS, with similar diagnostic problems with poor specificity as with laboratory based 
testing[65, 92, 93]. 
Molecular detection of nucleic acids are becoming more common, utilizing various molecular 
technologies. These can either utilize biological amplification (detection of ribosomal RNA) or 
laboratory based amplification technology like polymerase chain reaction (PCR)[94]. DNA 
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probes have been designed in commercially available assays targeting the 16S rRNA[95, 96]. 
These assays are estimated to be 1 log more sensitive as compared to EIA based assays. 
Specificity is reduced if samples are blood stained, as this may cause autofluorescence[2]. 
Some manufacturers also produce a confirmatory competitive assay, similar to those described 
for EIA[44, 97] to improve specificity. Furthermore, certain manufacturers offer combined 
assays testing for both Chlamydia trachomatis and Neisseria gonorrhea[98]. Nucleic acid 
amplification techniques offers the advantage of being highly sensitive and providing a 
platform for less invasive sampling[52]. Sensitivity may in fact be a diagnostic problem, as 
DNA amplification techniques have obtained positive results from environmental samples 
obtained from health care settings[2]. However, provided that sampling is performed with the 
same care as for culture, this should only be a theoretical diagnostic issue. Commercially 
available techniques utilized have largely focused on PCR[94, 99, 100], ligase chain 
reaction[101, 102] and strand displacement assays (SDA)[103], amongst others[104, 105]. 
Further development into real-time[106, 107] and multiplexed based platforms[108], as well as 
nesting steps[109] has also improved diagnostic utility.  
Inherent to the nature of nucleic acid detection methods, genetic variation may lead to a 
reduction in sensitivity of assays. A genetic variant was described in Sweden in 2007, which 
contained a 377bp deletion in the cryptic plasmid[9]. This resulted in false negative results 
by both the Roche COBAS AMPLICOR and Abbott LCx C trachomatis assays[110, 111], and 
on a community level, to unrestricted spread to these stains[110, 111]. For this reason, some 
authorities have called for all diagnostic assays to target at least two genetic sites within the 
pathogen[112]. 
3.2 Indirect detection 
Historically, serological testing has been used in investigation of women with pelvic 
inflammatory disease[113], ectopic pregnancies[114], recurrent miscarriages[12] and tubal 
infertility[115]. Despite this, serological testing to identify Chlamydia specific antibodies is 
not considered to be useful in the diagnosis of genital tract infection, for a number of 
reasons. Firstly, these antibodies are long-lived and do not distinguish between previous 
and current infection. Comparing antibody titers from acute and convalescent sera typically 
makes this distinction. This sampling window may be required to be as long as 1 month, 
and this type of diagnostic delay is not acceptable in modern laboratory medicine.  
Secondly, positivity is not specific for Chlamydia trachomatis, but rather Chlamydia spp., 
rendering interpretation of positive serology even more problematic[2]. Serological testing is 
considered appropriate in only two clinical settings. Firstly, use of Chlamydia specific IgM 
in the diagnosis of pneumonitis in infants, and secondly, significant rise in Chlamydial titers 
(≥32) in the diagnosis of LGV[24]. The practical application of this test is more difficult as the 
initial ulcers are typically painless and patients often do not present at health care facilities 
in the acute phase[2].  
Various testing procedures have been employed in detecting Chlamydial antibodies. 
Historically, complement fixation (CF) was utilized in many diagnostic laboratories. For this 
method, a single titer of ≥256 is strongly predictive of LGV versus a titer lower than 32 
showing good performance as a rule out test[116]. A further consideration with this assay is 
the requirement of biosafety level (BSL) 3 conditions[117]. Additionally, high quality 
antigen is not always available as these reagents are usually prepared from guinea pigs, 
which can be co-infected with Chlamydia psittaci [118].  
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Microscopic immunofluorescence testing (MIF) was long considered the test of choice for 
the diagnosis of chlamydial pneumonitis in infants, as this was utilized to identify IgM 
specifically[119, 120]. Historically, it was used in the description of the original 15 serovars 
described for Chlamydia trachomatis [121, 122]. This assay however is laborious and time-
consuming and is therefore usually not employed as a routine diagnostic test[2] as this 
antigen is produced from infected egg yolk in the form of elementary bodies[2].   
Enzyme immunoassay methods (EIA) are commercially available, typically targeting the 
LPS. A positive result in isolation does not distinguish between active or previous infection 
and may also be due to cross-reaction with antibodies for Chlamydia pneumonia or 
psittaci[123, 124]. Generally, EIA based testing is considered to be less sensitive compared to 
immunofluorescent-based testing[125], however, recently developed assays seem to show 
adequate sensitivity and specificity for use in a high throughput setting[126]. In a recent 
study by Baud et al, various serological platforms were evaluated. The CT-IgG-pELISA by 
Medac (Wedel, Germany) and automated epifluoroscence immunoassay by InoDiag (Signes, 
France) performed adequately, but still inferior to conventional immunofluorescence assays. 
The CT pELISA by R-Biopharm (Darmstadt, Germany) had sensitivities and specificities 
comparable to gold standard assays. These authors therefore considered this assay as an 
alternative option in a high throughput setting[126]. 
4. Defining the new “Gold Standard” assay 
The FDA expanded its definition of a true positive result in 1992 to include a combination of 
culture and non-culture based testing[127]. The Centers for Disease Control and Prevention 
(CDC) classifies diagnosis as definitive, presumptive and suggestive (Table 1)[87].  
 
Definitive 
Requires either of criteria 
1. Culture isolation with confirmation 
2. Any two of the following  
- DFA of exudate 
- EIA of exudate 
- NAT testing 
Presumptive 
Requires both criteria 
 Presence of clinical symptoms 
 Detection by non-culture based test 
Suggestive 
Requires 1st criterion with 
either 2nd or 3rd 
 Clinical symptoms 
 Exclusion of other causes of discharge or exudate 
 Sexual exposure to person with C trachomatis or 
nongonococcal urethritis, mucopurulent cervicitis or 
PID 
Table 1. Diagnostic criteria for Chlamydia trachomatis published by the CDC[87] 
The definition of the so-called “Gold Standard” testing assay is important for two reasons. 
Firstly, all commercially available tests will be measured against this standard to define 
performance characteristics.  In the past, performance was gauged simply on culture results, 
leading to overestimation of sensitivity[2]. And secondly, this will impact on testing 
algorithms depending on local epidemiology and prevalence[128]. The issue of prevalence is 
particularly complex in the case of Chlamydial infection as this not impacts on test 
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performance, but it has also been shown that females in low prevalence settings (defined as 
≤5%) seem to have a lower chlamydial load, further reducing testing sensitivity[129-131]. In 
its most extreme form, asymptomatic patients seem to have the worst sensitivity in 
testing[132]. Therefore, in these settings, the CDC advocates highly sensitive testing with 
confirmation of all positive samples[15].  
Recently, some authors have not only advocated use of NAT testing as the only gold 
standard[133], but rather specific assays like the BD ProbeTec ET (Becton Dickinson 
Diagnostic Systems, Maryland, USA), the COBAS TaqMan ST test v2.0 (Roche Diagnostics, 
New Jersey, USA) and the Aptima Combo 2 (Gen-Probe, San Diego, USA)[134]. Not only are 
these assays highly sensitive and specific, these can be easily implemented in a high 
throughput laboratory[133, 135-138]. 
5. Comparison of methods 
Currently, three molecular assays dominate molecular diagnostics of Chlamydia trachomatis. 
The Gen-Probe Aptima Combo 2 (AC2) targets the 23S rRNA molecule, whereas the Roche 
Cobas TaqMan CT assay targets both the cryptic plasmid and the omp1 gene. The Abbot 
RealTime CT m2000 PCR targets two parts of the cryptic plasmid[139]. All of these assays 
can successfully detect the new variant strain, first described in Sweden[140]. Despite very 
good performance by all these assays, the Gen-Probe assay seems to have superior 
sensitivity (99.3%) and equally good specificity (99.9%) as the Abbott m2000 assay. The 
Roche TaqMan assay shows superior specificity (100%), but with sensitivity estimated at 
82.4%[139]. These platforms have differing performance characteristics and use different 
pre-amplification processing steps. Since the quality of results is comparable, the true choice 
of assay lies by en large in the platform and pre-processing preferences.  
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